Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Comment by KayakerBCon Jul 18, 2017 11:12am
110 Views
Post# 26481094

RE:RE:RE:RE:RE:NASDAQ Listing Requirements

RE:RE:RE:RE:RE:NASDAQ Listing RequirementsAssuming the first human trial will be the Phase 0 Mtfp-trastuzumab trial, the June 13, 2017 news release stated:
 
"We have already selected a manufacturer to produce the clinical-grade fusion proteins required for the study. The development of the cell line to produce the fusion protein and the manufacturing of the required quantity of the drug will take up to a year to complete."

JD wrote: "My prediction is that we'll be on NASDAQ before a human gets a dose of anything with the peptide attached to it."

So combining the news release with JD's prediction, it will be at least until June 13th, 2018 before a Nasdaq listing.

That's not a logical conclusion from what was stated in the press release and by JD.  JD didn't predict that clinical-grade fusion proteins have to manufactured before we are on the NASDAQ.  

JD's prediction doesn't  preclude us from having a NASDAQ listing 3 months from now (or 2 or 4....).
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities